Did you mean 2017? Could be. Trials need to start 1st qtr 2016. If that doesn't happen I think things could get rough. IMO this is the make or break year for this company.
Thu, 31 Dec 2015 18:01:00 GMT ~ SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of PharmaCyte Biotech, Inc. (OTCMKTS: PMCB) answer; the above is concerning. must be why pps is dropping some.
[PR Newswire] - NEW YORK, Dec. 31, 2015 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of PharmaCyte Biotech Inc., ...
Wed, 30 Dec 2015 16:24:50 GMT ~ PharmaCyte Biotech End of Year Shareholder Update on Pancreatic Cancer and Diabetes Programs
[at noodls] - SILVER SPRING, Md., Dec. 30, 2015 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using ...
Wed, 30 Dec 2015 14:00:00 GMT ~ PharmaCyte Biotech End of Year Shareholder Update on Pancreatic Cancer and Diabetes Programs
[GlobeNewswire] - SILVER SPRING, Md., Dec. 30, 2015-- PharmaCyte Biotech, Inc., a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation ...
Thu, 17 Dec 2015 14:24:00 GMT ~ PharmaCyte’s Novel Diabetes Treatment Approach Could Prove Superior to Other Methods Under Development
[Accesswire] - BALTIMORE, MD / ACCESSWIRE / December 17, 2015 / Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has published a new ...
Business Description: PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as \"Cell-in-a-Box\" This unique and patented technology will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer and its symptoms, and diabetes are being developed. PharmaCyte Biotech's treatment for solid tumor cancers involves encapsulating modified live cells capable of converting the prodrug ifosfamide into its active or \"cancer-killing\" form. These encapsulated live cells are placed as close to the tumor as possible to enable the delivery of the highest levels of the cancer-killing drug at the source of the cancer. Ifosfamide is then given intravenously at one third the normal dose to eliminate adverse side effects. When the ifosfamide comes in contact with the encapsulated live cells through the circulatory system, the activation of the drug takes place at or near the tumor. This \"targeted chemotherapy\" has proven remarkably effective and safe to use in past clinical trials. PharmaCyte Biotech is also developing treatments for cancer based upon chemical constituents of the Cannabis plant. It is examining ways to exploit the benefits of Cell-in-a-Box technology in optimizing the anticancer effectiveness of Cannabis, while minimizing or outright eliminating the debilitating side effects usually associated with cancer treatments. In addition to developing treatments for pancreatic and other cancers, PharmaCyte Biotech is developing a treatment for Type 1 diabetes and Type 2 insulin-dependent diabetes. PharmaCyte Biotech plans to encapsulate a human cell line which has been genetically engineered to produce, store and secrete insulin on demand at levels in proportion to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box technology.Less >>
News 
Market Data 
Discover 
